US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist
  • 1.600
  • -0.040-2.44%
Close Nov 21 16:00 ET
  • 1.600
  • 0.0000.00%
Pre 08:00 ET
30.17MMarket Cap-1702P/E (TTM)

Chemomab Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
(Q1)Mar 31, 2022
(FY)Dec 31, 2021
(Q4)Dec 31, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-15.91%-23.61M
-31.31%-7.49M
-93.64%-7.19M
-64.62%-20.37M
-97.06%-5.7M
-103.68%-5.26M
-1.68%-5.7M
-187.01%-3.71M
-136.05%-12.37M
-86.11%-2.89M
Net income from continuing operations
12.39%-24.22M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-64.26%-8.27M
-172.24%-8.08M
-123.47%-6.19M
-199.53%-5.1M
-109.68%-12.48M
-158.12%-5.04M
Depreciation and amortization
15.52%67K
14.29%16K
23.08%16K
70.59%58K
27.27%14K
88.89%17K
100.00%14K
85.71%13K
41.67%34K
83.33%11K
Change In working capital
-123.66%-948K
40.21%-171K
110.87%1.07M
305.59%4.01M
61.62%1.82M
3,280.65%1.97M
91.52%-286K
40.17%506K
-451.17%-1.95M
214.57%1.12M
-Change in receivables
1,510.94%903K
99.73%-3K
324.24%814K
96.89%-64K
516.09%536K
129.95%883K
56.69%-1.12M
-736.84%-363K
-1,978.79%-2.06M
229.85%87K
-Change in payables and accrued expense
-135.50%-1.13M
-229.51%-531K
-62.68%315K
3,152.88%3.18M
48.56%1.24M
362.16%679K
145.56%410K
285.39%844K
-122.61%-104K
155.66%836K
-Change in other current liabilities
----
----
-125.00%-3K
----
----
--0
---27K
--12K
----
----
-Change in other working capital
-180.80%-724K
-20.18%360K
-553.85%-59K
320.66%896K
-89.00%22K
319.25%410K
292.17%451K
-84.71%13K
9.79%213K
106.19%200K
Cash from discontinued investing activities
Operating cash flow
-15.91%-23.61M
-31.31%-7.49M
-93.64%-7.19M
-64.62%-20.37M
-97.06%-5.7M
-103.68%-5.26M
-1.68%-5.7M
-187.01%-3.71M
-136.05%-12.37M
-86.11%-2.89M
Investing cash flow
Cash flow from continuing investing activities
-18.71%15.88M
-347.13%-4.27M
505.88%14.43M
143.23%19.53M
147.75%9.35M
221.48%6.07M
108.38%1.73M
119,200.00%2.38M
-72,780.65%-45.19M
-652,600.00%-19.58M
Net PPE purchase and sale
95.59%-3K
81.82%-2K
92.86%-1K
71.06%-68K
99.23%-1K
---42K
89.22%-11K
-366.67%-14K
-518.42%-235K
-12,900.00%-130K
Net investment purchase and sale
----
-345.45%-4.27M
502.38%14.43M
----
----
----
--1.74M
--2.4M
----
----
Net other investing changes
-18.97%15.88M
----
----
143.61%19.6M
148.07%9.35M
----
----
----
---44.95M
---19.45M
Cash from discontinued investing activities
Investing cash flow
-18.71%15.88M
-347.13%-4.27M
505.88%14.43M
143.23%19.53M
147.75%9.35M
221.48%6.07M
108.38%1.73M
119,200.00%2.38M
-72,780.65%-45.19M
-652,600.00%-19.58M
Financing cash flow
Cash flow from continuing financing activities
533.66%3.5M
-101.32%-808K
-972.84%-869K
154.17%39K
1,185.77%61.07M
-114.39%-81K
Net common stock issuance
468.45%3.5M
----
----
-101.62%-951K
-945.05%-951K
--0
----
----
1,575.34%58.64M
-118.20%-91K
Proceeds from stock option exercised by employees
--0
----
----
1,330.00%143K
720.00%82K
--39K
----
----
-99.20%10K
-98.22%10K
Net other financing activities
----
----
----
----
----
----
----
----
--2.43M
--0
Cash from discontinued financing activities
Financing cash flow
533.66%3.5M
6,118.18%1.37M
--0
-101.32%-808K
-972.84%-869K
154.17%39K
-99.84%22K
--0
1,185.77%61.07M
-114.39%-81K
Net cash flow
Beginning cash position
-10.79%13.6M
49.81%20.84M
-10.79%13.6M
29.97%15.24M
-71.38%10.82M
-78.09%9.96M
-76.11%13.91M
29.97%15.24M
-4.51%11.73M
197.01%37.8M
Current changes in cash
-157.02%-4.23M
-162.80%-10.39M
645.22%7.25M
-146.81%-1.65M
112.32%2.78M
111.21%858K
69.08%-3.95M
-102.86%-1.33M
734.30%3.51M
-2,166.93%-22.56M
End cash Position
-31.10%9.37M
4.98%10.46M
49.81%20.84M
-10.79%13.6M
-10.79%13.6M
-71.38%10.82M
-78.09%9.96M
-76.11%13.91M
29.97%15.24M
29.97%15.24M
Free cash flow
-15.54%-23.61M
-31.09%-7.49M
-92.94%-7.19M
-62.04%-20.44M
-88.38%-5.7M
-105.31%-5.3M
-0.05%-5.71M
-187.42%-3.73M
-138.88%-12.61M
-94.60%-3.03M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(FY)Dec 31, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022(Q1)Mar 31, 2022(FY)Dec 31, 2021(Q4)Dec 31, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -15.91%-23.61M-31.31%-7.49M-93.64%-7.19M-64.62%-20.37M-97.06%-5.7M-103.68%-5.26M-1.68%-5.7M-187.01%-3.71M-136.05%-12.37M-86.11%-2.89M
Net income from continuing operations 12.39%-24.22M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-64.26%-8.27M-172.24%-8.08M-123.47%-6.19M-199.53%-5.1M-109.68%-12.48M-158.12%-5.04M
Depreciation and amortization 15.52%67K14.29%16K23.08%16K70.59%58K27.27%14K88.89%17K100.00%14K85.71%13K41.67%34K83.33%11K
Change In working capital -123.66%-948K40.21%-171K110.87%1.07M305.59%4.01M61.62%1.82M3,280.65%1.97M91.52%-286K40.17%506K-451.17%-1.95M214.57%1.12M
-Change in receivables 1,510.94%903K99.73%-3K324.24%814K96.89%-64K516.09%536K129.95%883K56.69%-1.12M-736.84%-363K-1,978.79%-2.06M229.85%87K
-Change in payables and accrued expense -135.50%-1.13M-229.51%-531K-62.68%315K3,152.88%3.18M48.56%1.24M362.16%679K145.56%410K285.39%844K-122.61%-104K155.66%836K
-Change in other current liabilities ---------125.00%-3K----------0---27K--12K--------
-Change in other working capital -180.80%-724K-20.18%360K-553.85%-59K320.66%896K-89.00%22K319.25%410K292.17%451K-84.71%13K9.79%213K106.19%200K
Cash from discontinued investing activities
Operating cash flow -15.91%-23.61M-31.31%-7.49M-93.64%-7.19M-64.62%-20.37M-97.06%-5.7M-103.68%-5.26M-1.68%-5.7M-187.01%-3.71M-136.05%-12.37M-86.11%-2.89M
Investing cash flow
Cash flow from continuing investing activities -18.71%15.88M-347.13%-4.27M505.88%14.43M143.23%19.53M147.75%9.35M221.48%6.07M108.38%1.73M119,200.00%2.38M-72,780.65%-45.19M-652,600.00%-19.58M
Net PPE purchase and sale 95.59%-3K81.82%-2K92.86%-1K71.06%-68K99.23%-1K---42K89.22%-11K-366.67%-14K-518.42%-235K-12,900.00%-130K
Net investment purchase and sale -----345.45%-4.27M502.38%14.43M--------------1.74M--2.4M--------
Net other investing changes -18.97%15.88M--------143.61%19.6M148.07%9.35M---------------44.95M---19.45M
Cash from discontinued investing activities
Investing cash flow -18.71%15.88M-347.13%-4.27M505.88%14.43M143.23%19.53M147.75%9.35M221.48%6.07M108.38%1.73M119,200.00%2.38M-72,780.65%-45.19M-652,600.00%-19.58M
Financing cash flow
Cash flow from continuing financing activities 533.66%3.5M-101.32%-808K-972.84%-869K154.17%39K1,185.77%61.07M-114.39%-81K
Net common stock issuance 468.45%3.5M---------101.62%-951K-945.05%-951K--0--------1,575.34%58.64M-118.20%-91K
Proceeds from stock option exercised by employees --0--------1,330.00%143K720.00%82K--39K---------99.20%10K-98.22%10K
Net other financing activities ----------------------------------2.43M--0
Cash from discontinued financing activities
Financing cash flow 533.66%3.5M6,118.18%1.37M--0-101.32%-808K-972.84%-869K154.17%39K-99.84%22K--01,185.77%61.07M-114.39%-81K
Net cash flow
Beginning cash position -10.79%13.6M49.81%20.84M-10.79%13.6M29.97%15.24M-71.38%10.82M-78.09%9.96M-76.11%13.91M29.97%15.24M-4.51%11.73M197.01%37.8M
Current changes in cash -157.02%-4.23M-162.80%-10.39M645.22%7.25M-146.81%-1.65M112.32%2.78M111.21%858K69.08%-3.95M-102.86%-1.33M734.30%3.51M-2,166.93%-22.56M
End cash Position -31.10%9.37M4.98%10.46M49.81%20.84M-10.79%13.6M-10.79%13.6M-71.38%10.82M-78.09%9.96M-76.11%13.91M29.97%15.24M29.97%15.24M
Free cash flow -15.54%-23.61M-31.09%-7.49M-92.94%-7.19M-62.04%-20.44M-88.38%-5.7M-105.31%-5.3M-0.05%-5.71M-187.42%-3.73M-138.88%-12.61M-94.60%-3.03M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data